(Udenyca OnBody), which is a biosimilar of pegfilgrastim (Neulasta). vs 26%) and pain in the extremity (4% vs 9%). Leukocytosis was
(Neulasta, Fulphila, Udenyca. Ziextenzo). Hematopoietic Syndrome of Acute Udenyca; non-preferred agents will be Fulphila, Udenyca, and Nyvepria.
Clinical Policy: Pegfilgrastim (Neulasta, Neulasta Onpro), Pegfilgrastim-jmdb for acute radiation syndrome to Neulasta and Udenyca to align with other.
Updated policy name from pegfilgrastim (Neulasta; Neulasta Onpro; Fulphila; Udenyca; Ziextenzo, and move Neulasta/Neulasta Onpro to non-preferred
Laboratory studies comparing Udenyca with Neulasta have shown that the active substance in Udenyca is highly similar to that in Neulasta in terms of structure
Neulasta and Udenyca are the preferred pegfilgrastim products. Coverage will be provided for Neulasta and Udenyca contingent on the
Pegfilgrastim-cbqv (Udenyca) was compared to pegfilgrastim (Neulasta) for immunogenicity, adverse reactions, safety, pharmacokinetics, and
Udenyca (pegfilgrastim-cbqv), Ziextenzo (pegfilgrastim-bmez), Neulasta (pegfilgrastim), Neulasta Onpro (pegfilgrastim), and Fulphila (pegfilgrastim-jmdb).
Neulasta (pegfilgrastim), Nyvepria (pegfilgrastim-apgf), Udenyca Neulasta Onpro (pegfilgrastim), and Fulphila (pegfilgrastim-jmdb) are
then vs than
accept vs expect
alright vs all right
its vs it's
there vs their
waist vs waste
your vs you're, you are